We are live on
!
Find out more
Denali Therapeutics
DNLI
DNLI
222 hedge funds and large institutions have $1.85B invested in Denali Therapeutics in 2025 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 74 increasing their positions, 81 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
65% more call options, than puts
Call options by funds: $848K | Put options by funds: $515K
4.71% more ownership
Funds ownership: 88.89% → 93.6% (+4.7%)
3% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 34
0% less funds holding
Funds holding: 223 → 222 (-1)
9% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 81
29% less capital invested
Capital invested by funds: $2.61B → $1.85B (-$758M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
222
Holders Change
-1
Holders Change %
-0.45%
% of All Funds
2.98%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
35
Increased
74
Reduced
81
Closed
34
Calls
$848K
Puts
$515K
Net Calls
+$333K
Net Calls Change
-$267K
Top Buyers
| 1 |
UBS AM
Chicago,
Illinois
|
+$61M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$38M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$29.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$25.1M |
| 5 |
Millennium Management
New York
|
+$20.9M |
